The featured clinical investigation article of the March 2017 issue of the Journal of Nuclear Medicine demonstrates that the PET radiotracer fluciclovine (fluorine-18; F-18) can help guide and monitor targeted treatment for recurrent prostate cancer, allowing for individualised, targeted therapy.
“This is the first study of its kind demonstrating changes in post-surgery radiotherapy target design with advanced molecular imaging in recurrent prostate cancer, with no demonstrated increase in early radiotherapy side effects,” explains Ashesh B. Jani, MD, of the Winship Cancer Institute of Emory University, Atlanta, Georgia.
For the study, 96 patients were enrolled in a clinical trial of radiotherapy for recurrent prostate cancer after prostatectomy.
All patients underwent initial treatment planning based on results from conventional abdominopelvic imaging (CT or MRI).
Forty-five of the patients then underwent treatment-planning modification (better defining the tumour-targeted area) after additionally undergoing abdominopelvic F-18-fluciclovine PET/CT.
No increase in toxicity was observed with this process.
The Emory researchers determined that the inclusion of F-18-fluciclovine PET information in the treatment planning process leads to significant differences in target volumes (the areas to receive radiotherapy).
It did result in higher radiation dose delivered to the penile bulb, but no significant differences in bladder or rectal radiation dose or in acute genitourinary or gastrointestinal toxicity.
These are preliminary results in a three-year study, which hypothesises that there will be an increase in disease-free survival for patients in the F-18-fluciclovine-modified treatment group over those in the standard treatment group.
This study could have implications beyond prostate cancer, Jani points out, “Our methodology is readily applicable to other novel imaging agents, and it may potentially facilitate improvement of cancer control outcomes.”
[hr] Source: Society of Nuclear Medicine